Building Infrastructure for Making Healthcare Accessible and Affordable to all - State Perspectives

AIMED, other consumer groups extend support to price cap on stents by the Health Ministry – Will increase self-reliance in high-end devices

Views: 1.6K
Mr Rajiv Nath ,Forum Coordinator , AIMeD - Association of Indian Medical Devices Industry

Rajiv Nath, Forum Coordinator , AIMeD – Association of Indian Medical Devices Industry

Extending support to the Government of India’s action for price caps of medical devices starting from stents to protect consumers has been actively welcomed by AIMED – Association of Indian Medical Devices industry, the apex body representing domestic medical devices manufacturers; other consumer groups; and Indian manufacturers.

Bejon Misra, Founder, Patient Safety & Access Initiative of India Foundation has applauded the Health Ministry's bold step to cap prices of stents

Bejon Misra, Founder, Patient Safety & Access Initiative of India Foundation has applauded the Health Ministry’s bold step to cap prices of stents

Drug-Eluting Stents (DES)  – Overall Overview

 

  • Were launched in 2001 by the US multinational with more than 85% share until 2010 when Indian DES started getting acceptability
  • Command a higher price as is popularly considered of better quality standards due to the clinical trials performed

Indian Drug-Eluting Stents (DES) – Overview

  • Current Indian Market is around 5.50 lakh stents per annum out of which more than 90% are DES.
  • Has witnessed growth at a speed of around 15% every year
  • Will become the second largest market after China by 2020
  • Indian DES have proven equivalent to & even better than  American DES on both clinical performance & quality standards
  • The Indian companies like Translumina and Meril have huge capacities and have already achieved close to 20% market share within 5 years of their launch.

Key Takeaways

  • Will bring relief for many poor patients for whom the cost of affording a drug-eluting stent had become prohibitive
  • Will ensure fair practices in this important sector
  • Will break industry-doctor nexus that strengthened due to lack of awareness
  • Will increase transparency in terms of pricing of DES
  • Will encourage rational use of stents with proper due diligence on the treatment method

Representatives of the multinational companies importing such devices – Key Objections

  • Will discourage innovation
  • Will deny access to quality products  from abroad

Most Popular

To Top